查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症微生物组测序市场 - 2017-2027年全球行业规模、份额、趋势、机会及预测 按组分、按技术、按应用、按最终用户、按公司和按地区划分
市场调查报告书
商品编码
1303137

癌症微生物组测序市场 - 2017-2027年全球行业规模、份额、趋势、机会及预测 按组分、按技术、按应用、按最终用户、按公司和按地区划分

Cancer Microbiome Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Component, By Technology, By Application, By End User, By company and By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球癌症微生物组测序市场预计将在2023-2027年的预测期内实现令人瞩目的增长。主要因素包括癌症发病率不断上升以及人们越来越重视微生物组在癌症领域的潜力，这些因素都推动了市场的增长。微生物组是生长或存在于唾液、皮肤层、人体口腔粘膜和胃肠道等环境中的微生物群落。微生物组测序是一种有价值的工具，用于研究和分析位于人体内外的微生物群体，以更好地了解人体微生物。微生物组研究的主要目的是了解微生物在人类健康和疾病中的作用和功能。支持市场增长的其他因素包括：测序成本的降低、研发活动的增加、全球癌症病例数量的指数级增长、临床试验数量的增加、基于微生物组的新型诊断工具的开发为医生提供支持、生物技术公司投资的增加、微生物组测序服务在疾病诊断和早期检测方面的需求增加、世界人口增加、对微生物组测序技术的使用意识增强、医疗保健支出增加、研究人员对了解微生物组在人类健康和疾病中的作用的兴趣增加，以及新兴子市场的巨大潜力。

癌症发病率上升支持市场增长。

肺癌、宫颈癌、乳腺癌、皮肤癌、咽喉癌等癌症发病率的上升促进了市场的增长。据世界卫生组织预测，到2020年，癌症将成为导致全球死亡的主要原因，约有1000万人死于癌症，即每6人中就有1人死于癌症。最常见的癌症是肺癌、结肠癌、直肠癌、前列腺癌和乳腺癌。由于饮酒、吸烟、不健康的饮食习惯和久坐不动的生活方式，癌症病例数量激增。因此，对癌症微生物组测序的需求正在上升，这反过来又促进了市场的增长。世界卫生组织指出，许多癌症如果能在早期发现就能得到有效治疗。

研究人员越来越重视微生物组的潜力，生物技术公司的支持不断增加。

微生物组在诊断和预防各种癌症方面的潜力受到越来越多的关注，这推动了市场的增长。各种研究人员正在研究微生物组在癌症领域的潜力。在生物技术公司的支持下，研究人员正在揭示微生物组对癌症进展和表现的影响。此外，癌症微生物组测序服务和产品的开发帮助研究界制定了发现与微生物组相关的新型癌症生物标志物的有效策略，这些生物标志物可用于开发用于临床的癌症微生物组测序产品。

可定制

根据给定的市场数据，TechSci Research根据公司的具体需求提供定制服务。以下是报告的定制选项：

公司信息

  • 其他市场参与者（最多5家）的详细分析和概况。

目录

第一章：产品概述

第二章：研究方法

第三章：执行摘要

第4章：COVID-19对全球癌症微生物组测序市场的影响

第五章：客户之声

第6章 全球癌症微生物组测序市场展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按组成部分（试剂盒和检测、软件、服务）
    • 按技术（下一代测序与聚合酶链反应）
    • 按应用（转化研究与临床诊断）
    • 按终端用户（生物技术和制药公司、学术和研究机构、医院和诊所、其他）
    • 按公司（2021年）
    • 按地区
  • 市场地图

第七章 : 北美癌症微生物组测序市场前景

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按组分
    • 按技术
    • 按应用
    • 按终端用户
    • 按国家
  • 北美：国家分析
    • 美国
    • 美国
    • 加拿大

第八章：欧洲癌症微生物组测序市场展望

  • 市场规模和预测
    • 按价值
  • 市场份额及预测
    • 按成分
    • 按技术
    • 按应用
    • 按终端用户
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 德国
    • 西班牙

第九章 : 亚太地区癌症微生物组测序市场前景展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按成分
    • 按技术
    • 按应用
    • 按终端用户
    • 按国家
  • 亚太地区国家分析
    • 中国
    • 中国
    • 印度
    • 韩国
    • 澳大利亚

第十章 : 南美癌症微生物组测序市场前景展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按成分
    • 按技术
    • 按应用
    • 按终端用户
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 巴西
    • 哥伦比亚

第十一章 ：中东和非洲癌症微生物组测序市场展望

  • 市场规模与预测
    • 按价值
  • 市场份额及预测
    • 按成分
    • 按技术
    • 按应用
    • 按终端用户
    • 按国家
  • 中东和非洲：国家分析
    • 南非 癌症微生物组测序
    • 沙特阿拉伯癌症微生物组测序
    • 阿联酋 癌症微生物组测序
    • 土耳其癌症微生物组测序
    • 埃及癌症微生物组测序

第十二章 ：市场动态

  • 驱动因素
  • 市场挑战

第13章 ：市场趋势与发展

第14章：竞争格局

  • Illumina, Inc.Eurofins Scientific SE QIAGEN NV Thermo Fischer Scientific, Inc.Oxford Nanopore Technologies plc.OraSure Technologies, Inc.加州太平洋生物科学公司Psomagen, Inc Prescient Medicine Holdings, Inc.Micronoma Inc.

第15章：战略建议

简介目录
Product Code: 14153

The global cancer microbiome sequencing market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors, including growing occurrences of cancer and increasing emphasis on the microbiome's potential in the field of cancer, are fueling the growth of the market. Microbiomes are the community of microorganisms that grow or exist in an environment, such as saliva, skin layers, oral mucosa of the human body, and the gastrointestinal tract. Microbiome sequencing is a valuable tool that is used to study and analyze the microbes groups located in or out of the human body to have a better understanding of human microbes. The main aim of a microbiome research study is to understand the role and function of microbes in human health and disease. The other factors supporting the market's growth are decreasing cost of sequencing, the rise in R&D activities, the exponential rise in the number of cancer cases worldwide, the increasing number of clinical trials, the rise in the development of novel diagnostic tools based on the microbiome for supporting physicians, increasing investments by biotechnology companies, rise in demand for microbiome sequencing services for diagnosis and early detection of the diseases, rise in world population, growing awareness of the use of microbiome sequencing technology, rise in the healthcare expenditure, rising interest of researchers in understanding the role of the microbiome in human health and disease, and immense potential for emerging submarkets.

The rising Prevalence of Cancer supports Market Growth.

Growing incidences of cancer, such as lung, cervical, breast, skin, throat, and others, are augmenting the growth of the market. According to WHO, in 2020, cancer is a major cause of death across the world, reporting approximately 10 million deaths, or about one in six deaths. The most common cancers are lung, colon and rectum, prostate cancers, and breast. There is a surge in the number of cases suffering from cancer caused due to consumption of alcohol, tobacco use, unhealthy eating choices, and sedentary lifestyle. Therefore, the need for cancer microbiome sequencing is rising, which in turn, bolsters the growth of the market. As per WHO, many cancers can be treated effectively if detected in an early stage.

Increasing Emphasis by Researchers on the Microbiome's Potential and Rising Support from Biotechnology Companies.

The rising focus on the microbiome's potential to diagnose and prevent various cancers is fueling the growth of the market. Various researchers are studying and researching the microbiome's potential in the field of cancers. Researchers are being supported by biotech companies to unravel insights pertaining to the microbiome's influence on cancer progression and manifestation. Furthermore, the development of cancer microbiome sequencing services and products has aided the research community in creating effective strategies for discovering novel cancer biomarkers allied with the microbiome, which could be used for the development of cancer microbiome sequencing products for clinical use.

Market Segmentation

The global cancer microbiome sequencing market is segmented into components, technology, application, end-user, and company. Based on components, the market is divided into kits & assays, software, and services. Based on technology, the market is divided into next-generation sequencing and polymerase chain reaction. Based on application, the market is divided into translational research and clinical diagnostics. Based on end-user, the market is divided into biotechnology & pharmaceutical companies, academic & research institutions, hospitals & clinics, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising incidences of cancer and a rise in R&D activities in the country.

Market Players

Illumina, Inc., Eurofins Scientific SE, QIAGEN NV, Thermo Fischer Scientific, Inc., Oxford Nanopore Technologies plc., OraSure Technologies, Inc., Pacific Biosciences of California, Inc., Psomagen, Inc, Prescient Medicine Holdings, Inc., and Micronoma Inc. are some of the leading companies operating in the market.

Report Scope

In this report, global cancer microbiome sequencing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Cancer Microbiome Sequencing Market, By component:

  • Kits & Assays
  • software
  • Services

Cancer Microbiome Sequencing Market, By technology:

  • Next-Generation Sequencing
  • Polymerase Chain Reaction

Cancer Microbiome Sequencing Market, By application:

  • Translational Research
  • Clinical Diagnostics

Cancer Microbiome Sequencing Market, By End User:

  • Biotechnology & Pharmaceutical Companies,
  • Academic & Research Institutions
  • Hospitals & Clinics
  • Others

Cancer Microbiome Sequencing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Europe & CIS
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Cancer Microbiome Sequencing Market

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Impact of COVID-19 on Global Cancer Microbiome Sequencing Market

5. Voice of Customer

6. Global Cancer Microbiome Sequencing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component (Kits & Assays, Software, Services)
    • 6.2.2. By Technology (Next Generation Sequencing v/s Polymerase Chain Reaction)
    • 6.2.3. By Application (Translational Research v/s Clinical Diagnostics)
    • 6.2.4. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Hospitals & Clinics, Others)
    • 6.2.5. By Company (2021)
    • 6.2.6. By Region
  • 6.3. Market Map

7. North America Cancer Microbiome Sequencing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Microbiome Sequencing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Canada Cancer Microbiome Sequencing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. Mexico Cancer Microbiome Sequencing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User

8. Europe Cancer Microbiome Sequencing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Microbiome Sequencing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. Germany Cancer Microbiome Sequencing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. United Kingdom Cancer Microbiome Sequencing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. Italy Cancer Microbiome Sequencing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Spain Cancer Microbiome Sequencing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. Asia-Pacific Cancer Microbiome Sequencing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Microbiome Sequencing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. India Cancer Microbiome Sequencing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Japan Cancer Microbiome Sequencing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User
    • 9.3.4. South Korea Cancer Microbiome Sequencing Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Component
        • 9.3.4.2.2. By Technology
        • 9.3.4.2.3. By Application
        • 9.3.4.2.4. By End User
    • 9.3.5. Australia Cancer Microbiome Sequencing Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Component
        • 9.3.5.2.2. By Technology
        • 9.3.5.2.3. By Application
        • 9.3.5.2.4. By End User

10. South America Cancer Microbiome Sequencing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Microbiome Sequencing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Argentina Cancer Microbiome Sequencing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. Colombia Cancer Microbiome Sequencing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User

11. Middle East and Africa Cancer Microbiome Sequencing Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Component
    • 11.2.2. By Technology
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Microbiome Sequencing Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Component
        • 11.3.1.2.2. By Technology
        • 11.3.1.2.3. By Application
        • 11.3.1.2.4. By End User
    • 11.3.2. Saudi Arabia Cancer Microbiome Sequencing Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Component
        • 11.3.2.2.2. By Technology
        • 11.3.2.2.3. By Application
        • 11.3.2.2.4. By End User
    • 11.3.3. UAE Cancer Microbiome Sequencing Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Component
        • 11.3.3.2.2. By Technology
        • 11.3.3.2.3. By Application
        • 11.3.3.2.4. By End User
    • 11.3.4. Turkey Cancer Microbiome Sequencing Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Component
        • 11.3.4.2.2. By Technology
        • 11.3.4.2.3. By Application
        • 11.3.4.2.4. By End User
    • 11.3.5. Egypt Cancer Microbiome Sequencing Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Component
        • 11.3.5.2.2. By Technology
        • 11.3.5.2.3. By Application
        • 11.3.5.2.4. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Illumina, Inc.
  • 14.2. Eurofins Scientific SE
  • 14.3. QIAGEN NV
  • 14.4. Thermo Fischer Scientific, Inc.
  • 14.5. Oxford Nanopore Technologies plc.
  • 14.6. OraSure Technologies, Inc.
  • 14.7. Pacific Biosciences of California, Inc.
  • 14.8. Psomagen, Inc
  • 14.9. Prescient Medicine Holdings, Inc.
  • 14.10. Micronoma Inc.

15. Strategic Recommendations